Stock Events

Stock Events

Harmony Biosciences 

$28.41
0
+$1+3.65% Wednesday 00:24

Statistics

Day High
28.41
Day Low
28.41
52W High
-
52W Low
-
Volume
144
Avg. Volume
-
Mkt Cap
1.64B
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5MayExpected
Q3 2025
Q4 2025
Next
0.38
0.55
0.71
0.88
Expected EPS
0.782729
Actual EPS
N/A

Financials

18.27%Profit Margin
Profitable
2020
2021
2022
2023
2024
2025
1.74BRevenue
317.37MNet Income

Analyst Ratings

$41.17Average Price Target
The highest estimate is 55.00.
From 6 ratings within the last 6 months. This is not an investment recommendation.
Buy
67%
Hold
17%
Sell
17%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HRMY.BOATS. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Jazz Pharmaceuticals
JAZZ
Mkt Cap8.35B
Jazz Pharmaceuticals competes in the narcolepsy market, directly challenging Harmony Biosciences' key product, Wakix.
Axsome Therapeutics
AXSM
Mkt Cap6.74B
Axsome Therapeutics has a pipeline addressing central nervous system disorders, including narcolepsy, making it a competitor.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap23.49B
Teva Pharmaceutical Industries offers products for sleep disorders, including narcolepsy, competing with Harmony Biosciences.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on neurological disorders and has a broad portfolio that could compete with Harmony Biosciences' treatments.
Supernus Pharmaceuticals
SUPN
Mkt Cap3.12B
Supernus Pharmaceuticals has a focus on central nervous system diseases, including treatments for sleep disorders.
Palatin Technologies
PTN
Mkt Cap2.45M
Palatin Technologies is involved in developing treatments for various conditions, including those affecting the central nervous system, potentially competing with Harmony.

About

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
Show more...
CEO
ISIN
US4131971040

Listings

XNAS
US
HRMY
BOATS
BOATS
HRMY.BOATS

0 Comments

Share your thoughts

FAQ

What is Harmony Biosciences stock price today?▼
The current price of HRMY.BOATS is $28.41 USD — it has increased by +3.65% in the past 24 hours. Watch Harmony Biosciences stock price performance more closely on the chart.
What is Harmony Biosciences stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Harmony Biosciences stocks are traded under the ticker HRMY.BOATS.
What is Harmony Biosciences market cap?▼
Today Harmony Biosciences has the market capitalization of 1.64B
When is the next Harmony Biosciences earnings date?▼
Harmony Biosciences is going to release the next earnings report on May 05, 2026.
What were Harmony Biosciences earnings last quarter?▼
HRMY.BOATS earnings for the last quarter are 0.38 USD per share, whereas the estimation was 0.88 USD resulting in a -56.61% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Harmony Biosciences revenue for the last year?▼
Harmony Biosciences revenue for the last year amounts to 1.74B USD.
What is Harmony Biosciences net income for the last year?▼
HRMY.BOATS net income for the last year is 317.37M USD.
When did Harmony Biosciences complete a stock split?▼
Harmony Biosciences has not had any recent stock splits.